Advances in the study of nitric oxide-donating drugs.
- Author:
Yi-hua ZHANG
1
;
Si-xun PENG
Author Information
1. Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, China. zyhtgd@sohu.com
- Publication Type:Journal Article
- MeSH:
Animals;
Anti-Inflammatory Agents, Non-Steroidal;
therapeutic use;
Antineoplastic Agents;
pharmacology;
therapeutic use;
Aspirin;
analogs & derivatives;
pharmacology;
therapeutic use;
Azo Compounds;
pharmacology;
Cardiovascular Diseases;
drug therapy;
Cell Line, Tumor;
Drug Design;
Humans;
Neoplasms;
drug therapy;
pathology;
Nitrates;
pharmacology;
therapeutic use;
Nitric Oxide;
metabolism;
Nitric Oxide Donors;
pharmacology;
therapeutic use;
Piperazines;
pharmacology;
Signal Transduction;
drug effects
- From:
Acta Pharmaceutica Sinica
2009;44(11):1200-1210
- CountryChina
- Language:Chinese
-
Abstract:
Nitric oxide (NO) as a messenger and/or effector plays important roles in vivo. The decreased availability of NO or dysfunction in NO signaling has often been implicated in the development and progression of diseases, and design and research of NO-donating drugs has become one of the important strategies in drug discovery. In connection with authors' scientific practice, this article reviews the recent advances in the research of NO-donating drugs.
